de Luca L, Vitale N, Giannolo B, Cafarella G, Piazza L, Cotrufo M
Institute of Cardiac Surgery, V. Monaldi Hospital, Second University of Naples Medical School, Italy.
J Thorac Cardiovasc Surg. 1993 Dec;106(6):1158-65.
The CarboMedics cardiac prosthesis (CarboMedics, Inc., Austin, Tex.) is a relatively new, low-profile bileaflet prosthesis. We report the results of a prospective mid-term evaluation of 426 CarboMedics prostheses implanted at our institution. Three hundred fifty patients had CarboMedics prostheses implanted in the mitral (n = 125), aortic (n = 149), or aortic and mitral positions (n = 76). Hospital mortality was 5.2%. Follow-up was 98% complete, with 478 patient/years and a mean follow-up of 19 months (range 1 to 42 months). Actuarial freedom from complications were calculated as follows (linearized rates in parentheses): late mortality 97% +/- 0.77% (2.7%), thromboembolism 98% +/- 0.4% (0.5%), anticoagulation-related hemorrhage 98.6% +/- 0.4% (0.4%), nonstructural dysfunction 98.5% +/- 0.6 (0.2%), valve-related mortality 91.5% +/- 0.7 (0.5%), valve failure 90.9% +/- 1% (0.7%), treatment failure 92.8% +/- 0.8% (0.7%), and all valve-related morbidity and mortality 90% +/- 2% (2.6%). According to our results, the CarboMedics valve has a low rate of complications that further improves the quality of life in patients with heart valve prostheses.
卡博梅迪克斯心脏瓣膜假体（卡博梅迪克斯公司，得克萨斯州奥斯汀）是一种相对新型的、低轮廓双叶瓣膜假体。我们报告了在我们机构植入的426个卡博梅迪克斯瓣膜假体的前瞻性中期评估结果。350例患者在二尖瓣（n = 125）、主动脉瓣（n = 149）或主动脉瓣和二尖瓣位置（n = 76）植入了卡博梅迪克斯瓣膜假体。医院死亡率为5.2%。随访完成率为98%，随访时间为478患者年，平均随访19个月（范围1至42个月）。并发症的精算无事件生存率计算如下（括号内为线性化率）：晚期死亡率97%±0.77%（2.7%），血栓栓塞98%±0.4%（0.5%），抗凝相关出血98.6%±0.4%（0.4%），非结构性功能障碍98.5%±0.6（0.2%），瓣膜相关死亡率91.5%±0.7（0.5%），瓣膜失败90.9%±1%（0.7%），治疗失败92.8%±0.8%（0.7%），以及所有瓣膜相关的发病率和死亡率90%±2%（2.6%）。根据我们的结果，卡博梅迪克斯瓣膜的并发症发生率较低，这进一步改善了心脏瓣膜假体患者的生活质量。
